Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma

Leuk Lymphoma. 2015;56(10):2986-8. doi: 10.3109/10428194.2015.1016931. Epub 2015 Mar 10.

Authors

Sylvain Carras¹, Caroline Regny¹, Michel Peoc'h², Julie Gervasoni², Remy Gressin¹, Jean-Yves Cahn¹, Lysiane Molina¹

Affiliations

¹ a Department of Hematology , Grenoble University Hospital , Grenoble , France.
² b Department of Anatomopathology , Grenoble University Hospital , Grenoble , France.

PMID: 25676034
DOI: 10.3109/10428194.2015.1016931

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged, 80 and over
Antineoplastic Agents / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Humans
Lenalidomide
Male
Plasmablastic Lymphoma / diagnosis*
Plasmablastic Lymphoma / drug therapy*
Plasmablastic Lymphoma / surgery
Retreatment
Stomach Neoplasms / diagnosis*
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / surgery
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives*
Treatment Outcome

Substances

Antineoplastic Agents
Thalidomide
Lenalidomide